US Stock Market Move | Thermo Fisher Scientific (TMO.US) rose nearly 10% in Q2, with a 14% year-on-year growth in operating profit.

On Thursday, Thermo Fisher Scientific (TMO.US) rose nearly 10% to $578.80. On the news front, the biotechnology and medical device company Thermo Fisher Scientific reported its second quarter performance ending on June 27, 2026. In the second quarter, the company achieved a revenue of $11.99 billion, an increase of 10% compared to the same period in 2025; on a non-GAAP basis, organic revenue increased by 5% compared to the previous year. On a GAAP basis, operating profit reached $2.09 billion, a 14% year-over-year increase, with an operating profit margin of 17.4% (compared to 16.9% in the same period last year); diluted earnings per share increased by 9% year-over-year to $4.68. On a non-GAAP basis, adjusted operating profit reached $2.735 billion, a 15% year-over-year increase, with an adjusted operating profit margin climbing to 22.8%; adjusted earnings per share increased by 13% year-over-year to $6.03. Looking at specific business segments, Thermo Fisher Scientific's four core areas all achieved year-over-year revenue growth: Laboratory Products and BioPharma Services, the largest business pillar, contributed revenue of $6.693 billion in the second quarter, accounting for nearly 56% of total revenue, with a year-over-year growth of approximately 11.6%. Life Sciences Solutions achieved revenue of $2.815 billion, a 12.6% increase year-over-year. Analytical Instruments revenue reached $1.847 billion, a 6.9% increase year-over-year. Professional Diagnostics revenue reached $1.205 billion, a 6.3% increase year-over-year.